| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-09-08 | aducanumab (BIIB037) | Alzheimer's disease | 3 | Biogen (USA - MA) | Neurodegenerative diseases |
| 2015-09-08 | aducanumab (BIIB037) | Alzheimer's disease | 3 | Biogen (USA - MA) | Neurodegenerative diseases |
| 2015-09-08 | FPA008 (cabiralizumab) and Opdivo® (nivolumab) | non-small cell lung cancer, melanoma, head and neck squamous cell cancer, pancreatic cancer, colorectal cancer, glioblastoma multiforme | 1 | Five Prime Therapeutics (USA - CA) BMS (USA - NY) | Cancer - Oncology |
| 2015-09-08 | CER-001 | acute coronary syndromes | 2 | Cerenis Therapeutics (France) | Cardiovascular diseases |
| 2015-09-08 | VTS-270 - 2-hydroxypropyl-?-cyclodextrin | Niemann-Pick disease type C1 | 2b-3 | Sucampo Pharmaceuticals (USA - MA) | Rare diseases - Genetic diseases |
| 2015-09-08 | 89Zr-Df-IAB2M | prostate cancer | 2 | ImaginAb (USA - CA) | Cancer - Oncology - Technology - Services |
| 2015-09-08 | bavituximab | Peregrine Pharmaceuticals (USA - CA) | Cancer - Oncology | ||
| 2015-09-08 | RHB-105 (amoxicillin, rifabutin and omeprazole) | Helictobacter pylori infection | 3 | RedHill Biopharma (Israel) | Infectious diseases |
| 2015-09-07 | vintafolide | folate receptor (FR) positive recurrent non-small cell lung cancer (NSCLC) | 2b | Endocyte (USA - IN) | Cancer - Oncology |
| 2015-09-07 | Opdivo® (nivolumab) | advanced, squamous cell non-small cell lung cancer (NSCLC) | 3 | BMS (USA - NY) | Cancer - Oncology |
| 2015-09-07 | Opdivo® (nivolumab) | advanced squamous cell non-small cell lung cancer | 2 | BMS (USA - NY) | Cancer - Oncology |
| 2015-09-07 | ALLOB® | delayed union fractures | 1-2a | Bone Therapeutics (Belgium) | Bone diseases - Regenerative medicine |
| 2015-09-03 | GBR 830 | atopic dermatitis | 1 | Glenmark Pharmaceuticals (India) | Autoimmune diseases - Immunological diseases - Dermatological diseases |
| 2015-09-02 | AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase; HIRMAb-IDUA) | Hurler syndrome or mucopolysaccharidosis type I (MPS I) | 1 | Armagen (USA - CA) | Rare diseases - Genetic diseases |
| 2015-09-02 | fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) | HIV-1 infection | 3 | Gilead (USA - CA) | Infectious diseases |
| 2015-09-02 | CTL019 - tisagenlecleucel-T | chronic lymphocytic leukemia (CLL) | University of Pennsylvania (USA - PA) Novartis (Switzerland) | Cancer - Oncology | |
| 2015-09-02 | DCR-PH1 - synthetic double-stranded (hybridized duplex) ribonucleic acid oligonucleotide specific to hydroxyacid oxidase 1 gene | primary hyperoxaluria type 1 (PH1) | 1 | Dicerna Pharmaceuticals (USA - MA) | Rare diseases - Genetic diseases - Kidney diseases |
| 2015-09-01 | Praluent™ (alirocumab - SAR236553/REGN727) | patients with hypercholesterolemia who are at high or very-high cardiovascular (CV) risk, including patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) | 3 | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | Cardiovascular diseases - Genetic diseases - Rare diseases |
| 2015-09-01 | MEDI9197 | solid tumors | 1 | MedImmune (USA - global biologics arm of AstraZeneca (UK) | Cancer - Oncology |
| 2015-09-01 | triheptanoin (UX007) | cardiomyopathy due to long-chain fatty acid oxidation disorders (LC-FAOD) | Ultragenyx Pharmaceutical (USA - CA) | Rare diseases - Cardiovascular diseases |
